Press Releases 2010

  • 11/29/2010
    IntelGenx Acquires Full Ownership and Exclusive Rights to MS Induced Pain Product
  • 11/10/2010
    IntelGenx Reports Third Quarter 2010 Results and Highlights Recent Developments
  • 09/02/2010
    IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction Film Product
  • 08/30/2010
    IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product
  • 08/27/2010
    IntelGenx Announces Closing of Private Placement
  • 08/12/2010
    IntelGenx Reports Second Quarter 2010 Results and Highlights Recent Developments
  • 08/11/2010
    IntelGenx Announces Additions to Board and Issuance of Stock Options
  • 06/21/2010
    IntelGenx Reports on Meeting With FDA
  • 05/14/2010
    IntelGenx Reports First Quarter 2010 Results and Highlights Recent Developments
  • 05/14/2010
    IntelGenx Announces the Adjournment of the 2010 Annual General Meeting of Shareholders
  • 05/11/2010
    IntelGenx Acquires Full Ownership of High Dose Bupropion (CPI-300)
  • 05/04/2010
    IntelGenx Announces Manufacturing Partnership and Ownership Position in Manufacturing Facility
  • 04/21/2010
    IntelGenx Announces Licensing of Anti-Migraine Film Product
  • 04/07/2010
    IntelGenx to Present at BioFinance 2010
  • 03/31/2010
    IntelGenx Reports Q4 and Full Year 2009 Financial Results and Summarizes Development Milestones Achieved
  • 03/10/2010
    IntelGenx Granted Bupropion Patent
  • 03/04/2010
    IntelGenx and Cannasat Announce Letter of Intent for Relivar License
  • 02/08/2010
    IntelGenx Receives FDA Complete Response Letter CPI-300
  • 01/25/2010
    IntelGenx Enters Strategic Manufacturing Partnership for VersaFilm Technology
  • 01/22/2010
    IntelGenx Grants Options to IR Firm
  • 01/21/2010
    IntelGenx Receives Notice of Allowance for Bupropion Patent
  • 01/11/2010
    IntelGenx Announces Manufacturing Site Change for CPI-300